慢性病毒性肝病钙调节激素与骨密度的关系探讨

探讨慢性病毒性肝病患者骨密度及钙调节激素的变化及其间的相互关系。用NM—300单光子骨密度测量系统检测骨密度，空腹抽血检测钙调节激素：1，25二羟维生素D3[1，25(OH)2D3]、甲状旁腺素M(PTHM)、降钙素(CT)、骨钙素(BGP)。慢性肝炎和肝硬化组尺、桡骨宽度(BM)、骨密度(BMC)、骨矿物质含量(BMD)较对照组均降低，且随肝病的进程而加重；1，25(OH)2D3、BGP降低，PTHM、CT升高；1，25(OH)2D3、BGP与尺桡密度呈正相关，PTHM、CT与尺桡密度无相关。慢性病毒性肝病引起肝性骨病(BHD)在肝炎阶段已开始产生，BHD的发生主要是骨形成减少，而非骨破坏过多，1，25(OH)2D3的降低是其发生、发展的始动因素。

The relationship between calcium regulatory hormones and bone mineral density in patients with chronic virus liver diease

To study the relationship between bone mineral density (BMD) and serum calcium regulatory hormones in patients with chronic virus liver disease. NM-300 sigle-energy X-ray absorptiometry system was used to measure the BMD, The serum 1, 25(OH) 2D 3?PTHM?CT and BGP were also detected in these patients. BMD in patients with chronic virus liver disease were lower than those of controls. the serum 1, 25(OH) 2D 3 and BGP were lower, while PTH and CT were higher significantly than those of controls. The Changes of serum 1, 25(OH) 2D 3 and BGP were correlated with the changes of BMD. The hepatic bone disease (HBD)in Patients with chronic Liver disease (HBD) begin to happen when they were in the phase of hepatitis. HBD is mainly due to decrease of osteogenesis but not increase of osteonecrosis. The decrease of the serum 1, 25(OH) 2D 3 is the initial factor of HBD.